GB0316232D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
GB0316232D0
GB0316232D0 GBGB0316232.8A GB0316232A GB0316232D0 GB 0316232 D0 GB0316232 D0 GB 0316232D0 GB 0316232 A GB0316232 A GB 0316232A GB 0316232 D0 GB0316232 D0 GB 0316232D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0316232.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0316232.8A priority Critical patent/GB0316232D0/en
Publication of GB0316232D0 publication Critical patent/GB0316232D0/en
Priority to TW093119064A priority patent/TW200503691A/zh
Priority to SA4250204A priority patent/SA04250204B1/ar
Priority to BRPI0412472-3A priority patent/BRPI0412472A/pt
Priority to MXPA06000414A priority patent/MXPA06000414A/es
Priority to AU2004255999A priority patent/AU2004255999B2/en
Priority to DE602004014773T priority patent/DE602004014773D1/de
Priority to ES04749150T priority patent/ES2308204T3/es
Priority to JP2006520138A priority patent/JP2007521312A/ja
Priority to CNA2004800198411A priority patent/CN1823061A/zh
Priority to AT04749150T priority patent/ATE399777T1/de
Priority to PCT/SE2004/001114 priority patent/WO2005005417A1/en
Priority to CA002532056A priority patent/CA2532056A1/en
Priority to US10/564,235 priority patent/US7432288B2/en
Priority to EP04749150A priority patent/EP1646626B1/en
Priority to ARP040102419A priority patent/AR045721A1/es
Priority to KR1020067000712A priority patent/KR20060035748A/ko
Priority to RU2006102130/04A priority patent/RU2006102130A/ru
Priority to HK06108803.4A priority patent/HK1088320B/en
Priority to UY28408A priority patent/UY28408A1/es
Priority to MYPI20042745A priority patent/MY135821A/en
Priority to UAA200600272A priority patent/UA82109C2/uk
Priority to IL172760A priority patent/IL172760A0/en
Priority to NO20060081A priority patent/NO20060081L/no
Priority to ZA200600222A priority patent/ZA200600222B/en
Priority to IS8293A priority patent/IS8293A/is
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
GBGB0316232.8A 2003-07-11 2003-07-11 Therapeutic agents Ceased GB0316232D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
TW093119064A TW200503691A (en) 2003-07-11 2004-06-29 Therapeutic agents
SA4250204A SA04250204B1 (ar) 2003-07-11 2004-07-05 مشتقات بايرول-5،2-دايون pyrrole-2,5-dione كمعدلات مستقبل X الكبدي
HK06108803.4A HK1088320B (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators
CA002532056A CA2532056A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators
EP04749150A EP1646626B1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators
AU2004255999A AU2004255999B2 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver X receptor modulators
DE602004014773T DE602004014773D1 (de) 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
ES04749150T ES2308204T3 (es) 2003-07-11 2004-07-08 Derivados de pirrol-2,5-diona como moduladores del receptor x del higado.
JP2006520138A JP2007521312A (ja) 2003-07-11 2004-07-08 肝ｘ受容体調節薬としてのピロール−２，５−ジオン誘導体
CNA2004800198411A CN1823061A (zh) 2003-07-11 2004-07-08 用作肝脏x受体调节剂的吡咯－2,5－二酮衍生物
AT04749150T ATE399777T1 (de) 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
PCT/SE2004/001114 WO2005005417A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dione derivatives as liver x receptor modulators
BRPI0412472-3A BRPI0412472A (pt) 2003-07-11 2004-07-08 composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento e/ou prevenção de distúrbios lipìdicos (dislipidemia) associadas ou não com a resistência à insulina, e de aterosclerose, métodos de tratamento e/ou profilaxia de doença cardiovascular, de hipercolesterolemia, de condições associadas com a necessidade de se melhorar o transporte de colesterol reverso, e de se diminuir a absorção de colesterol no intestino, de de aumentar os nìveis de colesterol hdl, de se diminuir os nìveis de colesterol ldl, de condições inflamatórias, de mal de alzheimer, de arteriosclerose de diabetes tipo 2, de condições associadas com a necessidade de se melhorar a função de hdl, e, composição farmacêutica
US10/564,235 US7432288B2 (en) 2003-07-11 2004-07-08 Pyrrole-2,5-dione derivatives as Liver X receptor modulators
MXPA06000414A MXPA06000414A (es) 2003-07-11 2004-07-08 Derivados de pirrole-2,5-diona en la forma de moduladores del receptor de higado x.
ARP040102419A AR045721A1 (es) 2003-07-11 2004-07-08 Derivados de pirrol 2,5 diona como moduladores de receptores hormonales de higado
KR1020067000712A KR20060035748A (ko) 2003-07-11 2004-07-08 간 ｘ 수용체 조절물질로서 피롤-2,5-디온 유도체
RU2006102130/04A RU2006102130A (ru) 2003-07-11 2004-07-08 Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов
MYPI20042745A MY135821A (en) 2003-07-11 2004-07-09 Therapeutic agents
UY28408A UY28408A1 (es) 2003-07-11 2004-07-09 Agentes terapeuticos
UAA200600272A UA82109C2 (uk) 2003-07-11 2004-08-07 Похідні пірол-2,5-дитіону як модулятори х-рецептора печінки
IL172760A IL172760A0 (en) 2003-07-11 2005-12-22 Pyrrole-2,5-dithione derivatives as liver x receptor modulators
NO20060081A NO20060081L (no) 2003-07-11 2006-01-05 Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
ZA200600222A ZA200600222B (en) 2003-07-11 2006-01-10 Pyrrole-2,5-dione derivatives as Liver X receptor modulars
IS8293A IS8293A (is) 2003-07-11 2006-02-09 Pýrról-2,5-díónafleiður sem viðtakastillar lifrarX

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
GB0316232D0 true GB0316232D0 (en) 2003-08-13

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0316232.8A Ceased GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Country Status (25)

Country Link
US (1) US7432288B2 (https=)
EP (1) EP1646626B1 (https=)
JP (1) JP2007521312A (https=)
KR (1) KR20060035748A (https=)
CN (1) CN1823061A (https=)
AR (1) AR045721A1 (https=)
AT (1) ATE399777T1 (https=)
AU (1) AU2004255999B2 (https=)
BR (1) BRPI0412472A (https=)
CA (1) CA2532056A1 (https=)
DE (1) DE602004014773D1 (https=)
ES (1) ES2308204T3 (https=)
GB (1) GB0316232D0 (https=)
IL (1) IL172760A0 (https=)
IS (1) IS8293A (https=)
MX (1) MXPA06000414A (https=)
MY (1) MY135821A (https=)
NO (1) NO20060081L (https=)
RU (1) RU2006102130A (https=)
SA (1) SA04250204B1 (https=)
TW (1) TW200503691A (https=)
UA (1) UA82109C2 (https=)
UY (1) UY28408A1 (https=)
WO (1) WO2005005417A1 (https=)
ZA (1) ZA200600222B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1634877B1 (en) * 2004-08-17 2011-06-22 Simpson Biotech Co., Ltd. Mixture and compounds from mycelia of antrodia camphorata and use thereof
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
WO2007128458A1 (en) * 2006-04-28 2007-11-15 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
JP2013544837A (ja) 2010-12-03 2013-12-19 アラーガン インコーポレイテッド スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規オキシムアゼチジン誘導体
AU2011336970A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338866A1 (en) 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compound and pharmaceutical use thereof
ATE284387T1 (de) * 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
AU6593600A (en) 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
CA2532056A1 (en) 2005-01-20
NO20060081L (no) 2006-02-08
IS8293A (is) 2006-02-09
BRPI0412472A (pt) 2006-09-19
US20060235015A1 (en) 2006-10-19
TW200503691A (en) 2005-02-01
AU2004255999A1 (en) 2005-01-20
AU2004255999B2 (en) 2007-08-02
JP2007521312A (ja) 2007-08-02
ATE399777T1 (de) 2008-07-15
KR20060035748A (ko) 2006-04-26
US7432288B2 (en) 2008-10-07
MY135821A (en) 2008-07-31
UA82109C2 (uk) 2008-03-11
WO2005005417A1 (en) 2005-01-20
IL172760A0 (en) 2006-04-10
AR045721A1 (es) 2005-11-09
CN1823061A (zh) 2006-08-23
ES2308204T3 (es) 2008-12-01
SA04250204B1 (ar) 2008-03-23
ZA200600222B (en) 2007-04-25
HK1088320A1 (en) 2006-11-03
EP1646626B1 (en) 2008-07-02
RU2006102130A (ru) 2007-08-20
UY28408A1 (es) 2005-02-28
EP1646626A1 (en) 2006-04-19
DE602004014773D1 (de) 2008-08-14
MXPA06000414A (es) 2006-03-17

Similar Documents

Publication Publication Date Title
GB0303910D0 (en) Therapeutic agents
GB0308318D0 (en) Therapeutic agents
GB0314079D0 (en) Therapeutic agents
GB0314057D0 (en) Therapeutic agents
GB0313250D0 (en) Therapeutic agents
GB0314261D0 (en) Therapeutic agents
GB0316237D0 (en) Therapeutic agents
GB0314049D0 (en) Therapeutic agents
GB0316232D0 (en) Therapeutic agents
GB0314129D0 (en) Therapeutic agents
GB0311859D0 (en) Therapeutic agents
GB0311201D0 (en) Therapeutic agents
GB0301350D0 (en) Therapeutic agents
GB0314136D0 (en) Therapeutic agents
GB0314130D0 (en) Therapeutic agents
GB0314260D0 (en) Therapeutic agents
GB0304524D0 (en) Therapeutic agents
GB0314075D0 (en) Therapeutic agents
GB0314134D0 (en) Therapeutic agents
GB0314131D0 (en) Therapeutic agents
GB0314078D0 (en) Therapeutic agents
GB0304417D0 (en) Therapeutic agents
GB0314061D0 (en) Therapeutic agents
GB0305280D0 (en) Therapeutic agents
GB0305281D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)